Indivior agrees to pay out $385M to end yearslong Suboxone litigation and accusations it prevented generic competition
Virginia-based Indivior will pay out $385 million to bring an end to litigation over accusations it prevented generic competition to its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.